TC-S 7005

Cat. No.:	HY-108597
CAS No.:	1082739-92-1
Molecular Formula:	$C_{21}H_{17}N_3O_3$
Molecular Weight:	359.38
Target:	Polo-like Kinase (PLK)
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (347.82 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.7826 mL	13.9128 mL	27.8257 mL
	5 mM	0.5565 mL	2.7826 mL	5.5651 mL
	10 mM	0.2783 mL	1.3913 mL	2.7826 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC_{50}s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively[1].

IC_{50} & Target

PLK2	PLK3	PLK1
4 nM (IC_{50})	24 nM (IC_{50})	214 nM (IC_{50})

In Vitro

TC-S 7005 markedly induces myofibroblast differentiation and reduces fibroblast proliferation rates[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[2]

Cell Line:	Primary human SR fibroblasts
Concentration:	1 μM
Incubation Time:	7 days
Result:	Markedly induced myofibroblast differentiation and reduced fibroblast proliferation rates.

CUSTOMER VALIDATION

- Exp Cell Res. 2022 May 4.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Hanan EJ, et al. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5186-9.

[2]. Stephan Reinhard Künzel, et al. Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation. bioRxiv 445098

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA